Silk Road Medical has a Cash Ratio of 8.18. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Silk Road Medical's Cash Ratio or its related term are showing as below:
SILK'
s Cash Ratio Range Over the Past 10 Years
Min: 1.44 Med: 7.54 Max: 13.51
Current: 8.18
During the past 7 years, Silk Road Medical's highest Cash Ratio was 13.51. The lowest was 1.44. And the median was 7.54.
SILK's Cash Ratio is ranked better than 91.46% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.23
vs SILK: 8.18
Silk Road Medical Cash Ratio Historical Data
The historical data trend for Silk Road Medical's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's Cash Ratio
For the Medical Devices subindustry, Silk Road Medical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Cash Ratio falls into.
Silk Road Medical Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Silk Road Medical's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (NAS:SILK) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Silk Road Medical Cash Ratio Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical (Silk Road Medical) Business Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your 